Search Results

Your search for Weijing Sun, MD, FACP matches 2 pages

Showing 1 - 2

By Weijing Sun, MD, FACP / June 10, 2015

Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?

The phase III RAISE trial—reported by Tabernero and colleagues in The Lancet Oncology1 and reviewed in this issue of The ASCO Post—demonstrated that ramucirumab (Cyramza), a fully human IgG1 monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR2) extracellular domain, in...

colorectal cancer

By Matthew Stenger / June 10, 2015

Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer

In the phase III RAISE trial reported in The Lancet Oncology, Josep Tabernero, MD, PhD, Head of Medical Oncology at Vall d’Hebron Institute of Oncology, Barcelona, and colleagues found that the addition of the antiangiogenic anti–vascular endothelial growth factor receptor 2 (VEGFR2) antibody...

Apr

Today In Oncology

Search Results

Your search for Weijing Sun, MD, FACP matches 2 pages

Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?

Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer

Financial Hardships Caused by Cancer Are Long-Lasting for Many Working-Age Adults

MRI-Guided Duration of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Immunotherapy Plus FOLFIRI for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

AUA ASCO and SUO Publish 2024 Amendment to Nonmetastatic Muscle Invasive Bladder Cancer Guidelines

Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma